Systems and methods for removing pulmonary emboli
Through catheter system and method that generates countercurrent in the pulmonary vasculature, the limited and risk problems of pulmonary embolism treatment in the prior art are solved, safe and efficient removal of pulmonary embolism is achieved, and systemic therapeutic agents are avoided. use.
Patent Information
- Application Number
- CN202380026600.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-10
- Filing Date
- 2023-03-09
- Publication Date
- 2024-11-01
AI Technical Summary
Existing treatments for pulmonary embolism are limited, especially in complex and advanced disease situations, anticoagulation methods are ineffective, systemic fibrinolytics have a risk of bleeding, surgical and catheter-based methods are limited by blood vessel and catheter size, and insufficient navigation capabilities , cannot effectively remove pulmonary embolism.
Through catheter-based systems and methods, the suction catheter and the maintenance catheter generate countercurrent within the pulmonary vasculature, close the target pulmonary artery vessels, provide suction to remove emboli, and optionally locally administer the agent to avoid systemic therapeutic agents The use of the need to reduce catheter navigation through small lung vessels.
The safe and effective removal of pulmonary embolics is achieved, the risk of treatment is reduced, the use of systemic therapeutic agents is avoided, and the safety and effectiveness of treatment is improved.
Smart Images

Figure HDA0005035662430000011 
Figure HDA0005035662430000012 
Figure HDA0005035662430000013
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to and the benefit of U.S. Provisional Patent Application No. 63 / 318,490, filed on March 10, 2022, entitled “SYSTEM AND METHOD FOR REMOVING PULMONARY EMBRIUM,” the entire contents of which are incorporated herein by reference. Technical Field
[0003] The present disclosure relates to catheter-based devices, systems, and methods of use thereof for removing pulmonary emboli. Background Art
[0004] Acute pulmonary embolism is a significant cause of death worldwide, accounting for more than 100,000 deaths each year in the United States alone. An acute pulmonary embolism (PE), or embolus, is a blockage of a pulmonary (lung) artery. Most often, the condition is caused by a blood clot that forms in the legs or elsewhere in the body, such as a deep vein thrombosis (DVT), that travels to the lungs. After myocardial infarction and stroke, PE is the third leading cause of death from cardiovascular disease. Modern medical treatments for acute PE are generally divided into four categories: systemic anticoagulation; catheter-based fibrinolysis; systemic fibrinolysis; and surgical pulmonary embolectomy. Treatment may include a combination of these therapies.
[0005] However, current treatments are limited and may present significant risks to the patient. Anticoagulation approaches are often ineffective, especially in complex and / or advanced disease profiles. Systemic fibrinolytics have significant bleeding-associated risks and often have contraindications, meaning that certain circumstances suggest or indicate that this particular technique should not be used. Surgical and catheter-based approaches are limited by vessel and / or catheter size, and by the limited navigation capabilities of existing catheter technologies, particularly through tortuous environments such as the human lung structure.
[0006] Thus, there remains a long-standing unmet need for techniques, devices, and systems that can address these and other problems in the art. Summary of the invention
[0007] The present disclosure relates to catheter-based systems, devices, and methods for removing pulmonary emboli. Certain embodiments of the disclosed systems, devices, and methods temporarily reverse blood flow within the pulmonary vasculature, facilitating displacement of trapped emboli. Advantageously, the disclosed systems, devices, and methods can effectively remove pulmonary emboli without necessarily requiring the administration of systemic therapeutic agents (or being able to reduce the use of such therapeutic agents) and without requiring catheter navigation through small pulmonary vessels. Therefore, the disclosed systems, devices, and methods can achieve safer and more effective treatment of PE.
[0008] In some embodiments, the system includes an aspiration catheter with a distal balloon and a second catheter for holding the mitral valve open during systole. In some embodiments, the second catheter may include a distal attachment to be able to hold the mitral valve open. In some embodiments, the distal balloon of the aspiration catheter may occlude the right pulmonary artery or the left pulmonary artery or subsequent pulmonary artery vessels.
[0009] Embodiments of the disclosed method include delivering a catheter-based component through the heart via the venous system to access the pulmonary vasculature. The method may also include: occluding a target pulmonary artery vessel to block normal blood flow; providing suction to allow reverse flow, embolus removal, and / or blood drainage; and optionally administering a medicament locally to the pulmonary vasculature. Administration of medicaments may include, for example, administration of anticoagulants, anti-inflammatory agents, antiplatelet agents, and / or other therapeutic agents. The method may also include delivering a catheter-based component to the mitral valve via the arterial system to prevent the mitral valve from closing during ventricular systole, thereby allowing an increase in back pressure to allow reverse flow of pulmonary blood flow.
[0010] Utilizing reversed pulmonary blood flow to remove emboli from blood vessels has been used as a neuroprotective procedure in stroke treatment, which also involves the formation of clots or emboli. Here, creating reverse flow in the pulmonary vasculature could be a safe and effective approach to treating PE.
[0011] To avoid severe cardiac disruption, blood flow reversal is preferably limited to a single lung or an area of lung tissue within a single lung. The device can be used to occlude blood flow in the target pulmonary artery vessel to initiate blood flow reversal in the target lung area. An external pump can be used to generate the negative pressure required for the reversal and to drain the retrograde blood and / or particulate matter. Assuming hemodynamic stability (steady blood flow and good circulation), the aspirated blood can pass through an inline filter (inline filter, built-in filter) disposed in the aspiration catheter before entering the low-pressure venous system to remove displaced emboli, or can be drained externally.
[0012] Once normal blood flow on the pulmonary artery side ceases, and negative pressure and / or retrograde drainage is established, greater pressure may be required to establish and maintain retrograde flow. To apply greater pressure, a component that prevents the mitral valve from closing can be inserted into the heart during normal heart rhythm, allowing pressure to be transmitted retrogradely during ventricular systole to the left atrium, through the desired pulmonary veins, and then into the target tissue, the lung. Thus, keeping the mitral valve open facilitates increased mitral regurgitation, which further helps maintain the retrograde flow of blood.
[0013] Additional features and advantages will be set forth in part in the following description and in part will be apparent from the description or may be learned through the practice of the embodiments disclosed herein. The objects and advantages of the embodiments disclosed herein will be realized and obtained through the elements and combinations particularly pointed out in the appended claims. It should be understood that the foregoing brief summary and the following detailed description are merely exemplary and illustrative and are not limitations of the embodiments disclosed or claimed herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] A more particular description of the invention briefly described above will be given by reference to specific embodiments shown in the accompanying drawings. It should be understood that these drawings depict only typical embodiments of the invention and are not limiting of its scope, and the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings, in which:
[0015] Figure 1A-Figure 1D A cross-sectional anatomical overview of blood flow is shown in one embodiment of the disclosed reverse flow system, showing only one pulmonary artery and vein.
[0016] Figure 2A-2D A schematic overview of blood flow according to one embodiment of the disclosed reverse flow system is shown.
[0017] Figure 3 A catheter-based system for removing pulmonary emboli used in a reverse flow system is shown.
[0018] Figure 4 shows that using Figure 3 A catheter-based system is shown for reversing blood flow through lung tissue and facilitating removal of one or more pulmonary emboli. DETAILED DESCRIPTION
[0019] The present disclosure relates to catheter-based systems, devices, and methods for removing pulmonary emboli. For example, embodiments of the disclosed systems, devices, and methods temporarily reverse blood flow within the pulmonary vasculature to facilitate displacement of trapped emboli. Beneficially, the disclosed systems, devices, and methods can effectively remove pulmonary emboli without the need for administration of systemic therapeutic agents or the need for catheter navigation through small pulmonary vessels.
[0020] In some embodiments, the system includes an aspiration catheter (also referred to herein as a first catheter, a first catheter-based device, or an aspiration catheter-based device) and a holding catheter (also referred to herein as a second catheter, a second catheter-based device, or a holding catheter-based device), the aspiration catheter having an occluding component (such as a balloon) (e.g., disposed at or near the distal end), the holding catheter being used to hold the mitral valve open or at least temporarily interrupt mitral valve function during heart systole to increase mitral regurgitation.
[0021] In some embodiments, the second catheter may include a valve attachment capable of engaging the mitral valve. In some embodiments, a balloon or other occlusive component of the suction catheter is used to occlude the pulmonary artery vessel. For example, the balloon of the suction catheter may be deployed to occlude the right pulmonary artery or the left pulmonary artery.
[0022] One embodiment of the disclosed method includes the steps of delivering an aspiration catheter to the heart via the venous system to access the pulmonary vasculature; occluding a target pulmonary artery vessel to block normal blood flow; providing suction via the aspiration catheter to achieve reverse flow and embolus removal; and optionally administering an agent locally to the pulmonary vasculature. For example, anticoagulants, anti-inflammatory agents, antiplatelet agents, and / or other therapeutic agents may be locally administered and delivered. The method may also include delivering a catheter-based component through the heart via the arterial system to prevent the mitral valve from completely closing during ventricular systole, thereby allowing an increase in back pressure to reverse pulmonary blood flow.
[0023] To avoid severe cardiac damage, blood flow reversal is preferably limited to a single lung or an area of lung tissue within a single lung. The device can be used to occlude blood flow in the target pulmonary artery vessel to initiate blood flow reversal. An external pump can be used to generate negative pressure for reversal and drain retrograde blood and / or particulate matter. The aspirated blood can travel through a filter (e.g., an inline filter) to remove displaced emboli before entering the low-pressure venous system, or can be drained externally.
[0024] Once normal blood flow on the pulmonary artery side ceases and negative pressure / retrograde drainage is established, more pressure modulation may be required to establish retrograde flow. Therefore, components that prevent the mitral valve from fully closing can be used to deliver pressure retrogradely to the left atrium to assist in retrograde blood flow.
[0025] Figure 1A-Figure 1D A cross-sectional anatomical overview of blood flow is shown with one embodiment of the disclosed reverse flow system, showing only one pulmonary artery and vein. It should be understood that the reverse flow system can be implemented in more than one pulmonary artery and vein.
[0026] Figure 1ANormal blood flow through the heart and lungs is shown, with deoxygenated blood flowing from the right atrium (RA) and right ventricle (RV), flowing to the lungs and alveoli through the pulmonary artery (PA), where it is oxygenated, flowing to the left atrium (LA) and left ventricle (LV) through the pulmonary vein (PV), and then distributed to the body through the aorta (AO).
[0027] Deoxygenated blood enters the right atrium of the heart from the venous system. The deoxygenated blood then passes through the tricuspid valve to the right ventricle of the heart, through the depicted pulmonary artery and into the lung structures (e.g., to the alveolar-capillary bed), where the blood is oxygenated. Freshly oxygenated blood leaves the lungs through the pulmonary veins and enters the left atrium of the heart. The oxygenated blood then travels through the mitral valve and into the left ventricle, and then into the aorta to be delivered to the entire body.
[0028] like Figure 1B As shown, a first catheter-based device 102 can be inserted into the right atrium (e.g., via a transfemoral approach, a transradial approach, or other suitable approach), through the right ventricle, and into the target pulmonary artery. Deploying an occluding member 106 (e.g., a balloon) in the target pulmonary artery interrupts flow through the pulmonary vessel and its associated downstream pulmonary vasculature.
[0029] Figure 1C The use of a first catheter-based device 102 to provide suction to reverse blood flow through the target pulmonary artery is shown. The negative pressure generated by the suction from the catheter-based device causes the reverse flow of blood. In an alternative embodiment, a separate suction catheter different from the first catheter 102 can be guided to an area near the location where the occluding member 106 has been deployed (e.g., such that the distal end is just distal to the occluding member 106) and used to provide suction.
[0030] Figure 1D Also shown is a second catheter-based device 104 being inserted into the left ventricle (e.g., via a transfemoral approach, a transradial approach, a transseptal approach, or other suitable approach) and then into the mitral valve. The second catheter-based device 104 can be deployed to hold the mitral valve open or at least increase the level of regurgitation. Combined with negative pressure and suction from the pulmonary artery side, holding the mitral valve open facilitates mitral regurgitation and further reverses blood flow (i.e., blood flows from the left side of the heart to the right side of the heart).
[0031] Figure 2A-2D A schematic overview of blood flow according to one embodiment of the disclosed reverse flow system is shown. Figure 2ANormal blood flow through the heart and lungs is shown. Deoxygenated blood enters the right side of the heart from the venous system. The deoxygenated blood travels through the right ventricle (RV) of the heart, through the right and left pulmonary arteries, and then into the lung structures (e.g., through the alveoli in the right and left lungs), where the blood is oxygenated. Freshly oxygenated blood leaves the lungs through the right and left pulmonary veins and enters the left atrium (LA) of the heart. The oxygenated blood then travels through the left atrium to the left ventricle (LV) via the mitral valve, and through the aorta for delivery to the entire body.
[0032] like Figure 2B As shown, the first catheter-based device 102 can be inserted into the right ventricle and can be deployed (e.g., by deploying the occluding component 106) to block the right pulmonary artery. Blocking the right pulmonary artery interrupts the normal flow of blood to the right lung. As shown, blood still flows normally through the left lung.
[0033] Figure 2C A first catheter-based device 102 is shown that provides suction to reverse blood flow through the right pulmonary artery while still blocking normal blood flow through the right pulmonary artery. The negative pressure generated by the suction from the first catheter-based device 102 causes the reverse flow of blood flow. As shown, blood still flows normally through the left lung.
[0034] Figure 2D A second catheter-based device 104 is shown being inserted into the left ventricle to increase mitral regurgitation. Figure 2A-2C The negative pressure and suction of the first catheter-based device 102 shown in FIG. 1 combine to keep the mitral valve open to facilitate mitral regurgitation, which increases back pressure within the target pulmonary vasculature throughout ventricular systole and further reverses blood flow through the right lung. As shown, blood still flows normally through the left lung.
[0035] Figure 3 A catheter-based system for removing pulmonary emboli used in a reverse flow system is shown. The reverse flow system may include an aspiration catheter 102 having an occluding member 106 (e.g., a balloon) and a holding catheter 104. The aspiration catheter 102 may be placed in the right pulmonary artery (RPA) or the left pulmonary artery (LPA), and the occluding member 106 may occlude the right pulmonary artery or the left pulmonary artery when expanded.
[0036] The suction catheter 102 may include an inline filter 108 and may be directed to the right side of the heart via, for example, the femoral vein. Blood may flow through the suction catheter 102 and inline filter 108 via a normal physiological pressure gradient or via an external pump 112 (e.g., a mechanical pump). One or more external filters may be used in addition or alternatively.
[0037] As shown, the retaining catheter 104 can be guided through the aorta to the left ventricle (or alternatively, guided to the left ventricle via a transseptal approach), where the valve appendage 110 can be deployed to hold the mitral valve open or at least interrupt the normal function of the mitral valve to increase regurgitation. For example, the retaining catheter 104 may include a selectively retractable stent-based device, a balloon, or other expansion element configured to limit mitral valve closure. Beneficially, by limiting mitral valve closure, the retaining catheter 104 facilitates mitral regurgitation, better allowing blood flow to flow backwards. During ventricular systole, promoting mitral regurgitation increases left atrial pressure. The increase in left atrial pressure combined with mitral regurgitation and reverse blood flow through the aspiration catheter can advantageously displace one or more pulmonary emboli.
[0038] Figure 4 The use of a catheter-based system (e.g. Figure 3 Method 400 for treating a patient with PE using a pulmonary artery (system shown in FIG. 4A ). For example, the method may include delivering a suction catheter to a right pulmonary artery or a left pulmonary artery (step 401). The method may also include expanding an occluding member (e.g., a balloon) associated with the suction catheter (e.g., connected to the distal end of the suction catheter) at step 402. In some embodiments, deployment of the occluding device blocks blood flow targeted to either the right pulmonary artery or the left pulmonary artery.
[0039] Alternatively, before deploying the occluding member, the suction catheter can be further introduced into the pulmonary artery system to target a specific sub-region of the lung. For example, the suction catheter can be guided into a target lobar artery or segmental artery to perform blood flow reversal and embolus removal for a specific lobe or segment.
[0040] Method 400 may also include: providing suction through the suction catheter to generate a negative pressure gradient in step 403; and causing blood flow reversal in step 404. The method may include causing the reversed blood flow to flow through a filter (e.g., an inline filter disposed in the suction catheter) and optionally back to the patient's venous system in step 405. The method may also include using the negative pressure gradient and blood flow reversal to remove one or more pulmonary emboli, thereby treating the patient's acute PE in step 406.
[0041] Method 400 may further include: delivering a retention catheter to the mitral valve at step 407; and deploying the retention catheter to prevent complete closure of the mitral valve and / or otherwise increase mitral regurgitation at step 408. Steps 407 and 408 may be performed simultaneously with any of steps 401-406.
[0042] Additional Terms and Definitions
[0043] While certain embodiments of the present disclosure have been described in detail with reference to specific configurations, parameters, components, elements, etc., these descriptions are illustrative and should not be construed as limiting the scope of the claimed invention.
[0044] Furthermore, it should be understood that for any given element or component of the described embodiments, any possible alternatives listed for that element or component may generally be used alone or in combination with each other, unless implicitly or explicitly stated otherwise.
[0045] In addition, the numbers used in the specification and claims to indicate quantities, components, distances or other measurements may be optionally modified by the term "about" or its synonyms. When the terms "about", "approximately", "substantially", etc. are used in conjunction with the stated amount, value or condition, it is understood to refer to an amount, value or condition that deviates from the stated amount, value or condition by less than 20%, less than 10%, less than 5%, less than 1%, less than 0.1% or less than 0.01%.
[0046] Any headings and sub-headings used herein are for organizational purposes only and are not meant to limit the scope of the description or the claims.
[0047] It will also be noted that, as used in this specification and the appended claims, the singular forms "a", "an" and "the" do not exclude plural referents unless the context clearly indicates otherwise. Thus, for example, an embodiment referring to a single referent (e.g., a "widget") may also include two or more such referents.
[0048] It should also be understood that the embodiments described herein may also include characteristics and / or features (e.g., components, parts, members, elements, parts and / or portions) described in one or more separate embodiments, and are not necessarily strictly limited to the features explicitly described for that particular embodiment. Therefore, the various features of a given embodiment may be combined with other embodiments of the present disclosure and / or incorporated into other embodiments of the present disclosure. Therefore, the disclosure of certain features associated with a specific embodiment of the present disclosure should not be interpreted as limiting the application or inclusion of the features to a specific embodiment. On the contrary, it should be understood that other embodiments may also include such features.
Claims
1. A system for treating pulmonary embolism, comprising: an aspiration catheter including an occlusion member attached at or near a distal end of the aspiration catheter; as well as a retaining catheter comprising a valve attachment attached at or near a distal end of the retaining catheter, The occluding component is configured to block normal blood flow through one or more pulmonary arterial vessels when expanded.
2. The system of claim 1, wherein the valve attachment comprises a stent-based device or a balloon.
3. The system according to claim 1 further includes a suction device, which is configured to provide suction to the one or more pulmonary arteries through the suction catheter to induce reverse flow of blood through the suction catheter.
4. The system of claim 3, wherein the suction device comprises an external pump.
5. The system of claim 1, wherein the occluding member comprises a balloon.
6. The system of claim 1, further comprising an inline filter disposed within the aspiration conduit.
7. A method for treating pulmonary embolism, the method comprising: delivering a first catheter to a target pulmonary arterial vessel, wherein the first catheter includes an occluding component disposed at or near a distal end; deploying the occluding member; and Suction is provided to the target pulmonary artery vessel to induce reverse flow of blood.
8. The method of claim 7, further comprising dislodging one or more pulmonary emboli.
9. The method of claim 8, further comprising removing one or more pulmonary emboli from the patient.
10. The method of claim 7, wherein providing suction to the target pulmonary artery vessel comprises delivering a suction catheter different from the first catheter to the target pulmonary artery vessel to provide suction.
11. The method of claim 7, wherein the step of providing suction to the target pulmonary artery vessel comprises providing suction through the first catheter.
12. The method of claim 7, wherein the method treats acute pulmonary embolism.
13. The method of claim 7, wherein the occluding member comprises a selectively expandable balloon.
14. The method according to claim 7, further comprising: providing a retaining catheter, wherein the retaining catheter includes a valve attachment at or near a distal end; as well as The valve attachment of the retaining catheter is deployed at or near the mitral valve to increase mitral regurgitation.
15. The method of claim 14, wherein increasing mitral regurgitation further causes reverse flow of blood.
16. The method of claim 7, further comprising passing the retrograde blood flow through a filter.
17. The method of claim 16, wherein the filter is an inline filter disposed in the first conduit.
18. The method of claim 16, further comprising returning the retrograde blood flow to the patient's venous system.
19. A method for treating pulmonary embolism, the method comprising: delivering a first catheter to a target pulmonary arterial vessel, wherein the first catheter is an aspiration catheter, and wherein the first catheter includes an occluding component disposed at or near a distal end; deploying the occluding component within the target pulmonary artery vessel; providing a retaining catheter, wherein the retaining catheter includes a valve attachment at or near a distal end; deploying a valve attachment of the retaining catheter at or near the mitral valve to increase mitral regurgitation; and Suction is provided to the target pulmonary artery vessel through the first catheter to induce reverse flow of blood.
20. The method according to any one of claims 7-19, performed using a system according to any one of claims 1-6.
